Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups
European Urology Mar 06, 2020
van Leenders GJLH, Kweldam CF, Hollemans E, et al. - Researchers intended to conduct a proof-of-principle study incorporating CR/IDC in the current GG. Between 1993 and 2000, All prostate biopsies of 1,031 men with screen-detected Pca were analyzed for the current GG (ranging from 1 to 5) and CR/IDC. This study recruited a sum of 406 individuals who had received radical prostatectomy (RP), 508 radiotherapies (RT), 108 surveillance, and eight hormonal therapy, and the treatment was unknown for one patient. Utilizing Harrell’s C-statistic, they compared outcome measurements and statistical analysis disease-specific survival (DSS), metastasis-free survival (MFS), and biochemical recurrence-free survival (BCRFS) after 15.1 yr (interquartile range 10.9–19.7 yr) follow-up. Compared with GG, the cGrade is a simple Pca grade modification with better discriminative values for DSS and MFS, especially affecting decision making in men with current GG2 Pca.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries